scholarly journals Tyrosinase (TYR) gene sequencing and literature review reveals recurrent mutations and multiple population founder gene mutations as causative of oculocutaneous albinism (OCA) in Pakistani families

Eye ◽  
2019 ◽  
Vol 33 (8) ◽  
pp. 1339-1346
Author(s):  
Muhammad Shakil ◽  
Gaurav V. Harlalka ◽  
Shamshad Ali ◽  
Siying Lin ◽  
Ilaria D’Atri ◽  
...  
2017 ◽  
Vol 1 (1) ◽  
Author(s):  
Faravareh Khordadpoor Deilamani ◽  
Mohammad Taghi Akbari

Background: Non syndromic oculocutaneous albinism type (OCA) is caused by mutations in tyrosinase (TYR), OCA2, TYRP1, MATP (SLC45A2), SLC24A5 and C10ORF11 genes. Screening for mutations is important in families with oculocutaneous albinism patients in order to accurately diagnose the albinism type, genetic counseling and future therapeutic purposes. Objectives: The Aim of this study was to investigate the founder effect of most frequent mutations in OCA patients. Methods: TYR gene was sequenced in 26 unrelated inbred OCA families as well as 56 unrelated healthy individuals. In addition, homozygosity mapping was performed using 13 STR markers for 6 OCA loci (TYR, OCA2, TYRP1, MATP (SLC45A2), SLC24A5 and C10ORF11 genes). Different mutations were found in these genes from which a single base duplication (c.286dupA) and two single base substitutions c.996G > A (p.M332I) and c.230G > A (p.R77Q) had the most frequencies among the OCA families. In order to investigate the founder effect of these mutations, the haplotypes of two STR markers (TYR-S1 and TYR-S2) inside the TYR gene were ascertained. Results: It was revealed that families with similar mutation harbored similar haplotype for the TYR STR markers too. Conclusions: We conclude that these mutations are possible founder mutations in the Iranian population.


PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e106656 ◽  
Author(s):  
Vadieh Ghodsinejad Kalahroudi ◽  
Behnam Kamalidehghan ◽  
Ahoura Arasteh Kani ◽  
Omid Aryani ◽  
Mahdi Tondar ◽  
...  

2019 ◽  
Author(s):  
Yang Liu ◽  
Li Song ◽  
Jianbo Shu ◽  
Yulian Fang ◽  
Chao Sun ◽  
...  

Abstract Background: To enhance our understanding on the diagnosis and treatment of neonatal hereditary spherocytosis (HS). Methods: We summarized the clinical data and gene test results of a neonatal HS caused by a new mutation of SPTB gene. Meanwhile, a comprehensive literature review was performed. Gene sequencing and analysis was carried out for the crucial splicing signals on the exons and introns of the 302 known pathogenic genes (e.g. ANK1, SPTA1, EPB42, SLC4A1 and SPTB) associated with the genetic deficiency of erythrocyte. Results: A 26-day-old girl presented jaundice, anemia, an increased count in peripheral blood reticulocyte and spherocyte, as well as positive findings in the acidified glycerol hemolysis test. Gene sequencing revealed a new mutation of c.3737delA P. (Lys1246fs) in the exon 16 of SPTB (14q23 | NM_000347.5) gene in the patient and her father. The mutation was a frame-shifting mutation, which may result in truncation of beta-haemoglobin in erythrocyte membrane and loss of its normal function, leading to the occurrence of diseases. Conclusion: For the neonates with jaundice and anemia, family history, erythrocyte index and peripheral blood smear findings contributed to the diagnosis of HS. Gene sequencing is helpful for the diagnosis. We identified a novel mutation of SPTB gene, which may be pathogenic through modulating the activity of β-spectrin in the erythrocyte membrane.


Blood ◽  
2017 ◽  
Vol 129 (10) ◽  
pp. 1260-1269 ◽  
Author(s):  
Borja Saez ◽  
Matthew J. Walter ◽  
Timothy A. Graubert

Abstract Alternative splicing generates a diversity of messenger RNA (mRNA) transcripts from a single mRNA precursor and contributes to the complexity of our proteome. Splicing is perturbed by a variety of mechanisms in cancer. Recurrent mutations in splicing factors have emerged as a hallmark of several hematologic malignancies. Splicing factor mutations tend to occur in the founding clone of myeloid cancers, and these mutations have recently been identified in blood cells from normal, healthy elderly individuals with clonal hematopoiesis who are at increased risk of subsequently developing a hematopoietic malignancy, suggesting that these mutations contribute to disease initiation. Splicing factor mutations change the pattern of splicing in primary patient and mouse hematopoietic cells and alter hematopoietic differentiation and maturation in animal models. Recent developments in this field are reviewed here, with an emphasis on the clinical consequences of splicing factor mutations, mechanistic insights from animal models, and implications for development of novel therapies targeting the precursor mRNA splicing pathway.


2014 ◽  
Vol 24 (2) ◽  
pp. 168-173 ◽  
Author(s):  
Yu-ying Lin ◽  
Ai-hua Wei ◽  
Xin He ◽  
Zhi-yong Zhou ◽  
Shi Lian ◽  
...  

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1753 ◽  
Author(s):  
Serena Di Cosimo ◽  
Valentina Appierto ◽  
Marco Silvestri ◽  
Giancarlo Pruneri ◽  
Andrea Vingiani ◽  
...  

Triple negative breast cancer (TNBC) patients not attaining pathological Complete Response (pCR) after neo-adjuvant chemotherapy (NAC) have poor prognosis. We characterized 19 patients for somatic mutations in primary tumor biopsy and residual disease (RD) at surgery by 409 cancer-related gene sequencing (IonAmpliSeqTM Comprehensive Cancer Panel). A median of four (range 1–66) genes was mutated in each primary tumor biopsy, and the most common mutated gene was TP53 followed by a long tail of low frequency mutations. There were no recurrent mutations significantly associated with pCR. However, half of patients with RD had primary tumor biopsy with mutations in genes related to the immune system compared with none of those achieving pCR. Overall, the number of mutations showed a downward trend in post- as compared to pre-NAC samples. PIK3CA was the most common altered gene after NAC. The mutational profile of TNBC during treatment as inferred from patterns of mutant allele frequencies in matched pre-and post-NAC samples showed that RD harbored alterations of cell cycle progression, PI3K/Akt/mTOR, and EGFR tyrosine kinase inhibitor-resistance pathways. Our findings support the use of targeted-gene sequencing for TNBC therapeutic development, as patients without pCR may present mutations of immune-related pathways in their primary tumor biopsy, or actionable targets in the RD.


Sign in / Sign up

Export Citation Format

Share Document